Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma–COPD overlap syndrome
Main Article Content
Keywords
AOCS, budesonide formoterol, endothelial function, immune function, lung function, tiotropium bromide
Abstract
Objective: To investigate the clinical efficacy of combining budesonide formoterol with tiotropium bromide for treating asthma–chronic obstructive pulmonary disease overlap syndrome (AOCS).
Methods: The data of 104 patients with AOCS admitted to our hospital from December 2019 to December 2020 were assessed, randomly and divided into an experimental group (comprising 52 patients, receiving drug combination therapy) and a conventional group (comprising 52 patients, receiving drug therapy alone). Patients’ clinical efficacy, pulmonary function, fractioned exhaled nitric oxide (FeNO), immune function, endothelial function, serum lipid peroxidation injury indexes, adverse reactions, and quality of life scores were compared.
Results: Prior to treatment, no significant differences were observed in various pulmonary function indicators, FeNO, immune function, endothelial function, and lipid peroxidation injury indexes between the two groups (P > 0.05). However, after treatment, all observation indexes in both groups improved to different levels, with the experimental group -demonstrating -significantly superior improvement, compared to the conventional group (P < 0.05). We also observed that adverse reactions in the experimental group were significantly lower than in the conventional group (P < 0.05).
Conclusion: The combination of budesonide formoterol to tiotropium bromide in treating asthma–COPD overlap syndrome may significantly improve pulmonary function, endothelial function, and immune status of patients and encourage the recovery of serum lipid peroxidation injury; therefore, this may deserve widespread adoption and application.
References
2. Eklöf J, Alispahic IA, Sivapalan P, Wilcke T, Seersholm N, Armbruster K, et al. Targeted antibiotics for chronic pulmonary diseases (TARGET ABC): Can targeted antibiotic therapy improve the prognosis of pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non--cystic fibrosis bronchiectasis, and asthma? A multicenter, randomized, controlled, open-label trial. Trials. 2022;23(1):817. 10.1186/s13063-022-06720-z
3. Gemicioglu B, Uzun H, Borekci S, Karaali R, Kurugoglu S, Atukeren P, et al. Focusing on asthma and chronic obstructive pulmonary disease with COVID-19. J Infect Develop Countries. 2021;15(10):1415–25. 10.3855/jidc.14611
4. Boulet LP, Hanania NA. When asthma and chronic obstructive pulmonary disease overlap; current knowledge and unmet needs. Immunol Allergy Clin North Am. 2022;42(3):499–505. 10.1016/j.iac.2022.05.001
5. Adrish M, Anand MP, Hanania NA. Phenotypes of asthma--chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am. 2022;42(3):645–55. 10.1016/j.iac.2022.04.009
6. Liang Y, Mak JCW. Inhaled therapies for asthma and chronic obstructive pulmonary disease. Curr Pharm Des. 2021;27(12):1469–81. 10.2174/1389201021666201126144057
7. Ismaila AS, Haeussler K, Czira A, Youn JH, Malmenäs M, Risebrough NA, et al. Fluticasone furoate/umeclidinium/-vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A network meta--analysis. Adv Ther. 2022;39(9):3957–78. 10.1007/s12325- 022-02231-0
8. Li A, Chan HP, Gan PXL, Liew MF, Wong WSF, Lim HF. Eosinophilic endotype of chronic obstructive pulmonary disease: Similarities and differences from asthma. Korean J Int Med. 2021;36(6):1305–19. 10.3904/kjim.2021.180
9. Shao KM, Bernstein JA. Asthma-chronic obstructive pulmonary disease overlap: The role for allergy. Immunol Allergy Clin North Am. 2022;42(3):591–600. 10.1016/j.iac.2022.04.002
10. Hudler A, Holguin F, Sharma S. Pathophysiology of asthma--chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am. 2022;42(3):521–32. 10.1016/j.iac.2022.04.008
11. Sharma S, Khurana S, Federman AD, Wisnivesky J, Holguin F. Asthma-chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am. 2020;40(4):565–73. 10.1016/j.iac.2020.07.002
12. Kaminsky DA, Irvin CG. The physiology of asthma-chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am. 2022;42(3):575–89. 10.1016/j.iac.2022.04.001
13. Dumitrache MD, Jieanu AS, Scheau C, Badarau IA, Popescu GDA, Caruntu A, et al. Comparative effects of capsaicin in chronic obstructive pulmonary disease and asthma (review). Exp Ther Med. 2021;22(3):917. 10.3892/etm.2021.10349
14. Sahu A, Swaroop S, Kant S, Banerjee M. Signatures for chronic obstructive pulmonary disease (COPD) and asthma: A comparative genetic analysis. Br J Biomed Sci. 2021;78(4):177–83. 10.1080/09674845.2021.1905988
15. Hanania NA, Miravitlles M. Pharmacologic management strategies of asthma-chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am. 2022;42(3):657–69. 10.1016/j.iac.2022.05.002
16. Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: An observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020;8(11):1106–20. 10.1016/S2213-2600(20)30415-X
17. D’Urzo AD, Price D, Kardos P, Maleki-Yazdi MR. Importance of distinguishing between asthma and chronic obstructive pulmonary disease in primary care. Can Fam Phys (Medecin de Famille Canadien). 2021;67(9):661–7. 10.46747/cfp.6709661
18. Long B, Rezaie SR. Evaluation and management of asthma and chronic obstructive pulmonary disease exacerbation in the emergency department. Emerg Med Clin North Am. 2022;40(3):539–63. 10.1016/j.emc.2022.05.007
19. Diver S, Brightling CE, Greening NJ. Novel therapeutic strategies in asthma-chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am. 2022;42(3):671–90. 10.1016/j.iac.2022.04.005
20. Huang K, Chung KF. Clinical assessment and utility of biomarkers in asthma-chronic obstructive pulmonary disease overlap. Immunol Allergy Clin North Am. 2022;42(3):631–43. 10.1016/j.iac.2022.04.004
21. Zhou XL, Zhao LY. Comparison of clinical features and outcomes for asthma-COPD overlap syndrome vs. COPD patients: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(3):1495–510. 10.26355/eurrev_202102_24857
22. Halpin DMG. What is asthma chronic obstructive pulmonary disease overlap? Clin Chest Med. 2020;41(3):395–403. 10.1016/j.ccm.2020.06.006
23. Gaffney AW. Disparities in disease burden and treatment of patients asthma and chronic obstructive pulmonary disease. Med Clin North Am. 2022;106(6):1027–39. 10.1016/j.mcna.2022.08.005
24. Hahn DL. Does the asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) exist? A narrative review from epidemiology and practice. Allergol Immunopathol. 2022;50(6):100–6. 10.15586/aei.v50i6.678
25. Jo YS, Rhee CK, Yoon HK, Park CK, Lim JU, An TJ, et al. Evaluation of asthma-chronic obstructive pulmonary disease overlap using a mouse model of pulmonary disease. J Inflam (Lond Engl). 2022;19(1):25. 10.1186/s12950-022-00322-x
26. Boulet LP. Early features of chronic obstructive pulmonary disease in patients with asthma: Is there ACO before ACO? Immunol Allergy Clin North Am. 2022;42(3):549–58. 10.1016/j.iac.2022.03.002
27. See KC, Ng J. Management of acute severe asthma and chronic obstructive pulmonary disease. Singapore Med J. 2022;63(9):535–41. 10.4103/SINGAPOREMEDJ.SMJ-2022-015
28. Li JT. Asthma chronic obstructive pulmonary disease and lower respiratory disorders. Ann Allergy Asthma Immunol. 2023;130(2):131. 10.1016/j.anai.2022.09.015
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.